IL6 and type 2 diabetes mellitus: Our interest was focused on IL-6, considering its master role as a pro-inflammatory and proatherogenic molecule, especially in T2DM [55], and the fact that IL-6 signaling pathway modulation by canakinumab has been demonstrated to reduce cardiovascular event rates, independent of lipid-lowering [56].